Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Ovarian Res ; 16(1): 204, 2023 Oct 19.
Artículo en Inglés | MEDLINE | ID: mdl-37858247

RESUMEN

BACKGROUND: Studies have shown that supplementation with recombinant human GH (rh-GH) during ovarian stimulation (OS) may improve the ovarian response and clinical outcomes of IVF. However, it remains unclear whether GH is associated with the ploidy status of embryos, and therefore, is unable to explain the underlying reason for the effect of GH on IVF outcomes. This study aimed to investigate whether GH supplementation in women with advanced maternal age (AMA) during OS is related to an increased probability of obtaining euploid blastocysts. METHODS: This was a single center retrospective cohort study. The data of all women aged 38-46 years who underwent their first preimplantation genetic testing for aneuploidy (PGT-A) cycle between January 2021 and June 2022 were reviewed. Patients in the GH group received 4 IU/day subcutaneous GH supplementation from the beginning of OS to the trigger day, and patients in the control group did not. A total of 140 patients in the GH group and 272 patients in the control group were included after 1:2 propensity score matching. RESULTS: The baseline and cycle characteristics between the two groups were similar. The proportion of cycles which obtained euploid blastocysts was significantly higher in the GH group than that in the control group (41.43% vs. 27.21%, P = 0.00). The GH group had a significantly higher euploid blastocyst rate per cohort (32.47% vs. 21.34%, P = 0.00) and mean euploid blastocyst rate per cycle (per biopsy cycle 0.35 ± 0.40 vs. 0.21 ± 0.33, P = 0.00; per OS cycle 0.27 ± 0.38 vs. 0.16 ± 0.30, P = 0.02). However, the benefit of GH was more significant in patients aged 38-40 years, but not significant in patients aged 41-46 years. Pregnancy outcomes were similar between the two groups after embryo transfer. CONCLUSIONS: GH supplementation during OS is associated with a significantly increased probability of obtaining euploid blastocysts in women aged 38-40 years, but this benefit is not significant in women aged 41-46 years. Our results explained the underlying reason for the effect of GH on IVF outcomes in existing studies, and might be helpful for AMA patients undergoing PGT-A cycles to obtain a better outcome meanwhile to avoid over-treatment. TRIAL REGISTRATION: NCT05574894, www. CLINICALTRIALS: gov .


Asunto(s)
Fertilización In Vitro , Diagnóstico Preimplantación , Adulto , Femenino , Humanos , Persona de Mediana Edad , Embarazo , Aneuploidia , Blastocisto , Suplementos Dietéticos , Fertilización In Vitro/métodos , Pruebas Genéticas/métodos , Hormona del Crecimiento/uso terapéutico , Hormona del Crecimiento/farmacología , Edad Materna , Inducción de la Ovulación , Diagnóstico Preimplantación/métodos , Estudios Retrospectivos
2.
Front Endocrinol (Lausanne) ; 14: 1117706, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36950683

RESUMEN

Background: Growth hormone (GH) supplementation has been shown to improve oocyte quality and live birth, but few studies have examined whether GH can reduce embryonic aneuploidy. Chromosomal abnormalities in preimplantation embryos have been regarded as the principal cause of implantation failure and miscarriage, and an increased percentage of aneuploid embryos has been observed in patient cohorts with unexplained recurrent pregnancy loss (RPL), recurrent implantation failure (RIF), and advanced maternal age. Methods: This prospective cohort study was conducted on women whose previous PGT-A cycle ended up with no transferrable blastocysts, or the aneuploidy rate was above 50% and no live birth was acquired. The participants were divided into GH co-treatment and comparison groups according to whether GH was administered in the subsequent PGT-A cycle. In addition, within the GH co-treatment group, the previous failed cycle constituted the self-control group. Results: 208 women were recruited in the study (GH co-treatment group: 96 women, comparison group: 112 women). Compared to the self-control and comparison groups, the rate of euploid blastocysts was significantly higher in the GH co-treatment group (GH vs self-control: 32.00% vs 9.14%, odds ratio [OR]: 4.765, 95% confidence interval [CI]: 2.420-9.385, P < 0.01; GH vs comparison: 32.00% vs. 21.05%, OR: 1.930, 95% CI: 1.106-3.366, P = 0.021), and their frozen embryo transfers resulted in more pregnancies and live births. In the subgroup analysis, for the <35 and 35-40 years groups, the euploidy rate in the GH co-treatment group was significantly higher than those in the self-control and comparison groups, but in the >40 years group, there was no difference in euploidy rate. Conclusion: Our study presents preliminary evidence that GH supplementation may ameliorate blastocyst aneuploidy and improve pregnancy outcomes in women who have previously experienced pregnancy failures along with high aneuploidy rates, particularly in those younger than 40 years. Therefore, the use of GH in such women should be considered. However, considering the limited sample size and mixed indications for PGT-A, further scientific research on the underlying mechanism as well as clinical trials with larger sample sizes are needed to confirm the effects and optimal protocols.


Asunto(s)
Aborto Habitual , Diagnóstico Preimplantación , Embarazo , Humanos , Femenino , Resultado del Embarazo , Hormona del Crecimiento/uso terapéutico , Diagnóstico Preimplantación/métodos , Estudios Prospectivos , Pruebas Genéticas/métodos , Aneuploidia , Blastocisto , Suplementos Dietéticos
3.
Hum Reprod ; 37(6): 1194-1206, 2022 05 30.
Artículo en Inglés | MEDLINE | ID: mdl-35413106

RESUMEN

STUDY QUESTION: What are the outcomes for patients who choose to move embryos diagnosed as abnormal by preimplantation genetic testing for aneuploidy (PGT-A) to a new institution for transfer after the diagnosing institution refused to transfer them? SUMMARY ANSWER: Many patients seek to have selected embryos with PGT-A abnormal trophectoderm biopsies transferred recognizing that these embryos can still offer a chance of pregnancy and live birth. WHAT IS KNOWN ALREADY: : PGT-A is a widely practiced method of selecting embryos for transfer based on biopsy of a few cells. Many clinical practices refuse to transfer PGT-A abnormal embryos even when there are no other 'normal' embryos available. STUDY DESIGN, SIZE, DURATION: This is a prospective cohort of 69 couples who, since 2014, moved a total of 444 PGT-A abnormal embryos previously refused transfer at their parent institutions to our practice. Among these, 50 patients have, thus far, undergone 57 transfer cycles of 141 embryos. PARTICIPANTS/MATERIALS, SETTING, METHODS: Embryos diagnosed at other institutions by PGT-A as abnormal (mostly using next generation sequencing) were moved to our academically affiliated private fertility and research center in New York City. Female age at retrieval was 41.35 ± 3.98 years, 74% were Caucasian, 12% Asian and 10% were of African descent. All embryos identified as PGT-A abnormal among prospectively identified couples were recorded in our center's registry. MAIN RESULTS AND THE ROLE OF CHANCE: Among the 144 embryos transferred 102 (72.3%) had only 1 or 2 chromosomal abnormalities, 30 (21.3%) had 3 or more and 9 (6.4%) were 'undiagnosed' because of degraded DNA, yet still had been refused transfer. Transfer of PGT-A abnormal embryos resulted in 8 live births, 11 miscarriages and no voluntary terminations. One child was born with a segmental duplication and required repair of coarctation of the aorta as a newborn. Many couples with only PGT-A abnormal embryos are willing to have their PGT-A abnormal embryos transferred and such transfers can result in the establishment of ongoing euploid pregnancies and live births. LIMITATIONS, REASONS FOR CAUTION: Findings in this case series represent couples who chose to have their embryos transferred after having been refused transfer elsewhere and may not be representative of the wider population of couples undergoing IVF with PGT-A in general. Not all abnormal phenotypes present in the immediate postnatal period so it will be important to continue to follow the development of these children. WIDER IMPLICATIONS OF THE FINDINGS: PGT-A can result in a clinics refusal to transfer embryos with abnormal PGT-A biopsies, even those with mosaic findings, consequently large numbers of infertile women are prematurely advised that their only chance of motherhood is through third-party egg-donation. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by intramural funds from the Center for Human Reproduction and the not-for-profit research Foundation for Reproductive Medicine, both in New York, NY, USA. N.G. and D.H.B. are listed as co-inventors on several U.S. patents. One of these patents (US Patent# 7,615,544) relates to pre-supplementation of hypo-androgenic infertile women with androgens, such as DHEA and testosterone and, therefore, at least peripherally related to the subject of this manuscript. N.G. and D.F.A. also received travel funds and speaker honoraria from several pharmaceutical and medical device companies, though none related to the here presented subject and manuscript. N.G. is a shareholder in Fertility Nutraceuticals and he and D.H.B. receive royalty payments from Fertility Nutraceuticals LLC. TRIAL REGISTRATION NUMBER: N/A.


Asunto(s)
Infertilidad Femenina , Diagnóstico Preimplantación , Aneuploidia , Biopsia , Estudios de Cohortes , Femenino , Fertilización In Vitro , Pruebas Genéticas/métodos , Humanos , Masculino , Embarazo , Diagnóstico Preimplantación/métodos , Estudios Prospectivos
4.
Reprod Biomed Online ; 36(2): 154-163, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29203382

RESUMEN

This study provides an overview of preimplantation genetic diagnosis (PGD) for single gene diseases and the management of expanding indications in the context of a fully financially covered service at Montpellier's regional hospital centre. Within the framework of a restrictive law ruling PGD in France, only the parental genetic risk can be studied in embryos (concurrent aneuploidy screening is not allowed). PCR-based techniques were developed combining mutation detection and closely linked short tandem repeat markers within or flanking the affected genes, and set up more than 100 different robust fluorescent multiplex assays for 61 monogenic disorders. This strategy was used to analyse blastomeres from cleavage-stage embryos. Overall, 893 cycles were initiated in 384 couples; 727 cycles proceeded to oocyte retrieval and 608 cycles to embryo transfer, resulting in 184 deliveries. Clinical pregnancy rate per transfer, implantation and miscarriage rates were 33.6%, 25.1% and 8.8%, respectively. Our PGD programme resulted in the birth of 214 healthy babies for 162 out of 358 couples (45.3%), constituting a relevant achievement within an organizational framework that does not allow aneuploidy screening but provides equal access to PGD, both geographically and socioeconomically. This is a rare example of a fully free-of-charge PGD service.


Asunto(s)
Diagnóstico Preimplantación/estadística & datos numéricos , Femenino , Francia , Enfermedades Genéticas Congénitas/diagnóstico , Hospitales Públicos/estadística & datos numéricos , Humanos , Masculino , Programas Nacionales de Salud , Embarazo , Estudios Retrospectivos
5.
Matrix Biol ; 57-58: 76-85, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-27496350

RESUMEN

Epidermolysis bullosa (EB), a phenotypically heterogeneous group of skin fragility disorders, is characterized by blistering and erosions with considerable morbidity and mortality. Mutations in as many as 18 distinct genes expressed at the cutaneous basement membrane zone have been shown to be associated with the blistering phenotype, attesting to the role of the corresponding proteins in providing stable association of the epidermis to the dermis through adhesion at the dermo-epidermal basement membrane zone. Thus, different forms of EB have been highly instructive in providing information on the physiological functions of these proteins as integral components of the supramolecular adhesion complexes. In addition, precise information of the underlying genes and distinct mutations in families with EB has been helpful in subclassification of the disease with prognostic implications, as well as for prenatal testing and preimplantation genetic diagnosis. Furthermore, knowledge of the types of mutations is a prerequisite for application of allele-specific treatment approaches that have been recently developed, including read-through of premature termination codon mutations and chaperone-facilitated intracellular transport of conformationally altered proteins to proper physiologic subcellular location. Collectively, EB serves as a paradigm of heritable skin diseases in which significant progress has been made in identifying the underlying genetic bases and associated aberrant pathways leading from mutations to the phenotype, thus allowing application of precision medicine for this, currently intractable group of diseases.


Asunto(s)
Membrana Basal/patología , Colágeno Tipo VII/genética , Epidermólisis Ampollosa/patología , Proteínas de la Matriz Extracelular/genética , Mutación , Piel/patología , Membrana Basal/metabolismo , Colágeno Tipo VII/química , Colágeno Tipo VII/metabolismo , Epidermólisis Ampollosa/clasificación , Epidermólisis Ampollosa/genética , Epidermólisis Ampollosa/metabolismo , Proteínas de la Matriz Extracelular/metabolismo , Expresión Génica , Heterogeneidad Genética , Genotipo , Humanos , Fenotipo , Diagnóstico Preimplantación , Diagnóstico Prenatal , Índice de Severidad de la Enfermedad , Piel/metabolismo
6.
Reprod Biol Endocrinol ; 13: 38, 2015 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-25943720

RESUMEN

BACKGROUND: Low functional ovarian reserve (LFOR) has been associated with hypoandrogenemia and increased embryo aneuploidy, while androgen supplementation has been reported to improve aneuploidy rates. We, therefore, assessed whether in infertile women undergoing in vitro fertilization (IVF) androgen concentrations are associated with aneuploidy rates. METHODS: This study was performed in 2 academically affiliated fertility centers in New York City and an academically affiliated steroid chemistry laboratory in Utah. Androgen concentrations were measured in blinded fashion from 84 infertile women (age 40.3+/-2.4 years) at New York University (NYU), using a validated LC-MS/MS method, in cryopreserved serum samples of patients who had undergone IVF with concomitant preimplantation genetic screening (PGS), utilizing a 24-chromosome platform. The Center for Human Reproduction (CHR) provided plasma samples of 100 historical controls (ages 38.6+/-5.0 years) undergoing IVF without PGS. Statistical comparisons were made of androgen concentrations, and of associations between androgen concentrations and embryo aneuploidy. RESULTS: Women undergoing IVF+PGS at NYU revealed no association between embryo aneuploidy and androgen concentrations but demonstrated significantly lower androgen concentrations than the 100 control patients from CHR, CONCLUSIONS: Though this study revealed no association between androgen levels and embryo ploidy, the extremely low androgen levels in the NYU study group raise the possibility of a threshold effect below which testosterone no longer affects aneuploidy. Before an androgen effect on embryo ploidy can be completely ruled out, a patient population with more normal androgen levels has to be investigated.


Asunto(s)
Aneuploidia , Infertilidad Femenina/metabolismo , Reserva Ovárica , Factores de Edad , Androstenodiona/sangre , Hormona Antimülleriana/sangre , Deshidroepiandrosterona/sangre , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Edad Materna , Diagnóstico Preimplantación , Factores de Riesgo , Testosterona/sangre
7.
Eur J Hum Genet ; 23(1): 34-40, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24690678

RESUMEN

Despite well-established protocols for the medical management of Von Hippel-Lindau disease (VHL), families affected by this rare tumour syndrome continue to face numerous psychological, social, and practical challenges. To our knowledge, this is one of the first qualitative studies to explore the psychosocial difficulties experienced by families affected by VHL. A semi-structured interview was developed to explore patients' and carers' experiences of VHL along several life domains, including: self-identity and self-esteem, interpersonal relationships, education and career opportunities, family communication, physical health and emotional well-being, and supportive care needs. Quantitative measures were also used to examine the prevalence of anxiety, depression, and disease-specific distress in this sample. Participants were recruited via the Hereditary Cancer Clinic at the Prince of Wales Hospital in Sydney, Australia. A total of 23 individual telephone interviews were conducted (15 patients, 8 carers), yielding a response rate of 75%. A diverse range of experiences were reported, including: sustained uncertainty about future tumour development, frustration regarding the need for lifelong medical screening, strained family relationships, difficulties communicating with others about VHL, perceived social isolation and limited career opportunities, financial and care-giving burdens, complex decisions in relation to childbearing, and difficulties accessing expert medical and psychosocial care. Participants also provided examples of psychological growth and resilience, and voiced support for continued efforts to improve supportive care services. More sophisticated systems for connecting VHL patients and their families with holistic, empathic, and person-centred medical and psychosocial care are urgently needed.


Asunto(s)
Familia , Enfermedad de von Hippel-Lindau/epidemiología , Adaptación Psicológica , Adolescente , Adulto , Anciano , Australia/epidemiología , Cuidadores , Niño , Preescolar , Anticoncepción , Femenino , Pruebas Genéticas , Humanos , Masculino , Persona de Mediana Edad , Diagnóstico Preimplantación , Investigación Cualitativa , Apoyo Social , Estrés Psicológico , Encuestas y Cuestionarios , Adulto Joven , Enfermedad de von Hippel-Lindau/diagnóstico , Enfermedad de von Hippel-Lindau/genética
8.
Reprod Biol Endocrinol ; 8: 140, 2010 Nov 10.
Artículo en Inglés | MEDLINE | ID: mdl-21067609

RESUMEN

BACKGROUND: Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy chances in women with diminished ovarian reserve (DOR), and to reduce miscarriage rates by 50-80%. Such an effect is mathematically inconceivable without beneficial effects on embryo ploidy. This study, therefore, assesses effects of DHEA on embryo aneuploidy. METHODS: In a 1:2, matched case control study 22 consecutive women with DOR, supplemented with DHEA, underwent preimplantation genetic screening (PGS) of embryos during in vitro fertilization (IVF) cycles. Each was matched by patient age and time period of IVF with two control IVF cycles without DHEA supplementation (n = 44). PGS was performed for chromosomes X, Y, 13, 16, 18, 21 and 22, and involved determination of numbers and percentages of aneuploid embryos. RESULTS: DHEA supplementation to a significant degree reduced number (P = 0.029) and percentages (P < 0.001) of aneuploid embryos, adjusted for relevant covariates. Short term supplementation (4-12 weeks) resulted in greatest reduction in aneuploidy (21.6%, 95% CI -2.871-46.031). DISCUSSION: Beneficial DHEA effects on DOR patients, at least partially, are the likely consequence of lower embryo aneuploidy. DHEA supplementation also deserves investigation in older fertile women, attempting to conceive, where a similar effect, potentially, could positively affect public health.


Asunto(s)
Aneuploidia , Trastornos de los Cromosomas/prevención & control , Deshidroepiandrosterona/uso terapéutico , Ovario/patología , Diagnóstico Preimplantación , Aborto Espontáneo , Adulto , Estudios de Casos y Controles , Femenino , Fertilización In Vitro , Pruebas Genéticas , Humanos , Embarazo , Índice de Embarazo , Estudios Retrospectivos
9.
Reprod Biomed Online ; 21(3): 280-2, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20692207

RESUMEN

Preimplantation genetic diagnosis (PGD) should not be an option only for the few couples at risk of serious genetic conditions who can afford it. We appear to have lost sight of the original driving force behind the development of PGD, which is that most couples who carry a serious genetic disorder find it more acceptable to choose to conceive with healthy embryos tested in-vitro at preimplantation stages of development within the first week following fertilization, even if that means discarding those diagnosed as affected. It has been shown using cystic fibrosis as an example, that the cost savings to the US healthcare system of providing free IVF-PGD to all carrier couples compared to the lifetime costs of medical treatment for patients affected by this disease, run to dozens of billions of dollars. With the increasing emphasis in medicine on early diagnosis and prevention of disease together with the availability of new molecular genetic diagnostic tools, a national IVF-PGD programme seems to be the next step in modern health care.


Asunto(s)
Diagnóstico Preimplantación , Análisis Costo-Beneficio , Femenino , Fertilización In Vitro , Enfermedades Genéticas Congénitas/diagnóstico , Enfermedades Genéticas Congénitas/prevención & control , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Programas Nacionales de Salud , Embarazo , Diagnóstico Preimplantación/economía , Diagnóstico Preimplantación/historia , Diagnóstico Preimplantación/tendencias , Reino Unido
10.
J Med Humanit ; 31(4): 279-94, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20676739

RESUMEN

Theatre-based health policy research is an emerging field, and this article investigates the work of one of its leaders. In 2005, prominent medical geneticist and playwright Jeff Nisker and his collaborators produced Orchids, his play concerning pre-implantation genetic diagnosis, to research theatre as a tool for engaging citizens in health policy development. Juxtaposing Orchids with a concurrent disability theatre production in Vancouver entitled Ugly, I argue that disability theatre suggests important means for building inclusiveness in this kind of research and complicates Nisker's own call for international guidelines to delimit how journalists, playwrights, filmmakers, physicians and other media authors share genetics-based narratives in public.


Asunto(s)
Arteterapia/métodos , Personas con Discapacidad/rehabilitación , Drama , Política de Salud , Investigación sobre Servicios de Salud , Diagnóstico Preimplantación , Predisposición Genética a la Enfermedad , Humanos , Narración , Desarrollo de Programa , Evaluación de Programas y Proyectos de Salud
11.
Hum Reprod ; 24(12): 3108-18, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19726447

RESUMEN

BACKGROUND: Cross-border reproductive care indicates the cross-border movements made by patients to obtain infertility treatment they cannot obtain at home. The problem at present is that empirical data on the extent of the phenomenon are lacking. This article presents the data on infertility patients going to Belgium for treatment. METHODS: A survey was conducted among the centres for reproductive medicine that are allowed to handle oocytes and create embryos (B-centres). Data were collected on the nationality of patients and the type of treatment for which they attended during the period 2000-2007. RESULTS: Sixteen of 18 centres responded to the questionnaire. The flow of foreign patients has stabilized since 2006 at approximately 2100 patients per year. The majority of foreign nationals seeking treatment in Belgium were French women for sperm donation. The next highest group was patients entering the country to obtain ICSI with ejaculated sperm. CONCLUSIONS: There are clear indications that numerous movements are motivated by the wish to evade legal restrictions in one's home country, either because the technology is prohibited or because the patients have characteristics, which exclude them from treatment in their own countries.


Asunto(s)
Infertilidad/terapia , Turismo Médico/estadística & datos numéricos , Servicios de Salud Reproductiva/estadística & datos numéricos , Técnicas Reproductivas Asistidas/estadística & datos numéricos , Adulto , Bélgica , Femenino , Francia/etnología , Encuestas de Atención de la Salud , Humanos , Inseminación Artificial Heteróloga/estadística & datos numéricos , Masculino , Turismo Médico/tendencias , Persona de Mediana Edad , Programas Nacionales de Salud/legislación & jurisprudencia , Programas Nacionales de Salud/estadística & datos numéricos , Países Bajos/etnología , Selección de Paciente , Diagnóstico Preimplantación/estadística & datos numéricos , Técnicas Reproductivas Asistidas/legislación & jurisprudencia , Inyecciones de Esperma Intracitoplasmáticas/estadística & datos numéricos , Adulto Joven
12.
Reprod Biomed Online ; 17(4): 486-96, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18854101

RESUMEN

This review assesses the ability of non-invasive 'amino acid profiling' to predict early embryo viability. The history of amino acid supplementation of embryo culture media and the role of amino acids in early embryo development are first considered and these are followed by a review of methods to quantify amino acid depletion and production by single embryos. Data on amino acid profiling of embryos from a number of species are then discussed. It is concluded that this technology has excellent potential to improve the selection of single embryos for transfer in clinical IVF.


Asunto(s)
Aminoácidos/metabolismo , Blastocisto/metabolismo , Blastocisto/fisiología , Viabilidad Fetal , Diagnóstico Preimplantación/métodos , Aminoácidos/clasificación , Animales , Medios de Cultivo/química , Medios de Cultivo/farmacología , Técnicas de Cultivo de Embriones/métodos , Desarrollo Embrionario/fisiología , Femenino , Viabilidad Fetal/fisiología , Humanos , Modelos Biológicos , Embarazo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA